A recent study of 281 patients with extraesophageal syndromes of gastroesophageal refl ux disease, of whom 50% had a cough, estimated that 52% of the overall US national annual economic burden of extraesophageal syndromes was attributable to proton pump inhibitor therapy. 1 It is becoming increasingly important to identify patient populations likely to be responsive, avoiding unnecessary or inappropriate treatment. Xu et al 2 should be congratulated on their study recently published in CHEST (June 2014) applying the Gastroesophageal Refl ux Disease Questionnaire to predict patients with gastroesophageal refl ux-induced chronic cough (GERC) who may be responsive to antirefl ux ther apy. We have some questions and comments.
First, were any other common causes ruled out in the potential subjects with suspected GERC prior to participation ? A prospective multicenter study showed that cough-variant asthma (32.6%), upper airway cough syndrome (18.6%), eosinophilic bronchitis (17.2%), and atopic cough (13.2%) are among the most common causes of chronic cough in China, with GERC in only 4.6% of cases. 3 Xu et al 2 did not report any information about bronchial provocation test, induced sputum test, peripheral blood eosinophil count, or serum IgE level, suggesting that some common causes of chronic cough could not have been included, which might lead to unnecessary invasive tests and excessive treatment. Additionally, other information, such as smoking, body weight, and lifestyle modifi cation, was not reported, which would be useful and important.
Second, was it reasonable to establish the diagnosis based on favorable response to antirefl ux therapy? Empirical trial has been widely used in the diagnosis of GERC, since no diagnostic gold standard is available. However, diagnosis based exclusively on therapeutic response has been challenged with the increasing evidence 4 , 5 that patients benefi t little from acid-suppressive therapy and with the likely mechanisms of hypersensitivity and vagal refl ex.
Third, we wonder about the presence of other causes of chronic cough in some patients. Cough in 8.0% of patients resistant to initial acid-suppression therapy was resolved using baclofen as an add-on therapy. Indeed, baclofen could improve refractory cough attributed to gastroesophageal refl ux disease. However, baclofen, an agonist of g -aminobutyric acid, has also been shown to inhibit refractory cough due to other causes. In such cases, other possible causes responsive to baclofen would be considered in addition to GERC, impairing the predictive value of the Gastroesophageal Refl ux Disease Questionnaire . 
